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Figure 2. Kaplan-Meier curves for the bivariate comparisons.

Figure 1. Histologic features of chordoma.

BACKGROUND
Chordoma is a rare but locally aggressive malignant neoplasm showing
notochordal differentiation. The clinical differential diagnoses can be
extensive, and definitive diagnosis often relies on histopathologic
evaluation. Histologically, chordoma shows dual epithelial and
mesenchymal differentiation, with various morphologies. Despite surgical
resection and use of adjuvant radiation therapy, the local recurrence rate
of chordoma remains high. We aim to establish factors associated with the
increased risk of recurrence and help guide treatment decisions.
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DESIGN
We performed a retrospective study of patients diagnosed with chordoma
between 1990 and 2014 who underwent surgical treatment at our
institution. The study was approved by the Institutional Review Board at
TJUH. Pathologic database was searched, and 60 patients were identified,
with a total of 107 pathology cases. Medical charts were reviewed, and all
available pathology cases (n=94) were reviewed by two pathologists (W.J.
and S.M). Clinical and pathologic variables were recorded (see Tables 1
and 2). Overall survival (OS) was defined as [date of death/last follow-up date of diagnosis of primary tumor], and disease free survival (DFS) was
defined as [date of recurrence/metastasis - date of diagnosis of primary
tumor]. Log-rank tests were used to assess whether each potential
predictor affected the DFS. Analyses were performed using R 3.1.2 (R
Foundation for Statistical Computing, Vienna, Austria).

RESULTS
Table 1. Clinical variables
Age (yrs)

56.4 (19-83)

Sex (M:F)

1.3:1

Anatomic	
  
Site	
  

Race (n=56)

W = 89%, B = 7%, A = 4%

Clivus/skull base

40%

Vertebral body

40%

Sacrococcygeal bone

20%

Tumor size (cm) (n=42)

5.1 (1.6-15.0)

Radiation therapy

47.4%

Local recurrence (n=52)

42.3 %

Metastasis (n=52)

13.4%

Overall Survival (months) (n=56)

76 (2-257)

Disease free survival (months) (n=55)

61 (1-263)

Follow up time (months)

97 (1-232)
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Table 2. Pathologic variables (n=94)
Classic

86%

Chondroid

12%

De-differentiated

2%

Tumor heterogeneity

19%

Nuclear atypia

14%

Giant cells

49%

Mitotic activity

56%

Necrosis

26%

No radiation

Yes
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Figure 1. Classic (a), chondroid (b), and de-differentiated chordoma (c). In
de-differentiated chordoma, the brachyury staining is lost (f), whereas the
well-differentiated component (d) maintains the staining (e). Heterogeneity
defined as significant difference in histologic type, cellularity (g), and/or cytologic
atypia (h). Metastatic chordoma to skin dermis (i).

Statistical analyses
Using the log rank model, the only two variables that were near statistical
significance were radiation therapy (p=0.12) and tumor heterogeneity
(p=0.11) (see Table 3). When both radiation and tumor heterogeneity were
included in a Cox regression model, they were more significant but still had pvalues > 0.05. Radiation had a hazard ratio of 0.13 (95% CI 0.02-1.18, p =
0.070), and tumor heterogeneity, 4.78 (0.78-29.45, p = 0.09).
Table 3. Statistical analyses
Gender
Age
Race (non-white)
Tumor size
Anatomic site
Radiation
Tumor type
Tumor heterogeneity
Cellularity
Nuclear atypia
Mitotic activity
Necrosis

Bivariate log rank
0.103
0.742
0.497
0.149
0.680
0.117
0.440
0.109
0.921
0.455
0.173
0.211

For age and size, bivariate done with Cox regression

Full Cox
0.219
0.325
0.228
0.485
0.758
0.227
0.958
0.660
0.561
0.214
0.985
0.938

Our cohort is one of the largest clinicopathologic series of chordoma from
a single institution with long-term follow up data. A diagnosis of chordoma
may be challenging on both clinical and histological grounds. In our study,
CT and/or MRI were the main diagnostic imaging modalities, and the
radiologic differential diagnoses included chondrosarcoma, pituitary
adenoma (sellar region), nerve sheath tumor (cervical spine), meningioma,
lymphoma, and metastasis; chordoma was suspected in only 43% of
cases prior to surgery. In a few cases (n=6), the “physaliphorous” cells
were not prominent, and pathologic differential diagnosis included
metastatic renal cell carcinoma and chondrosarcoma. IHC for brachyury
showed diffuse positivity in all of these cases, with the exception of the dedifferentiated component in one case. Therefore, brachyury is helpful in
confirming the diagnosis of chordoma when the histology is not classic,
especially in the context of other commonly expressed antigens (S100,
CK19, EMA and AE1/AE3).
Tumor heterogeneity, defined as significant difference in tumor type,
cellularity, and/or cytologic atypia within the same tumor (Figure 1), and
radiation therapy, appear to have an effect on disease free survival, which
are interesting findings. Although they are not statistically significant, this
could be due to the underpower of the study.

FUTURE DIRECTIONS
The high rate of local recurrence seems to dictate the clinical outcome,
and our finding of histologic heterogeneity associated with local recurrence
is quite interesting. Larger multicenter studies are needed to validate the
result, which may influence the clinical management of these lesions.
Currently, the therapy for chordoma is largely limited to surgery and
radiation therapy. Adjuvant radiation therapy is considered standard of
care despite conflicting data regarding its effect on clinical outcome.
Understanding the molecular basis of the tumorigenesis is key to the
endeavor in finding new therapeutic regimen for these patients. We are
currently working on exploring the molecular pathways, by using IHC
analyses on tissue microarrays generated from this cohort. Whole-exome
sequencing will also help identify new genes and pathways important for
tumor development.
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